-
Some On Wall Street Still Back Valeant
Tuesday, March 15, 2016 - 11:51am | 558Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged 40 percent and touched a new 52-week low after the company reported a loss for its fourth quarter and slashed its outlook. The company cited incremental headwinds in Ophthalmology Rx, as well as the Commonwealth and Western Europe businesses...
-
BMO Downgrades Whole Foods And Bristol-Myers Squibb To Start Week: Why?
Monday, January 25, 2016 - 10:17am | 484Read More...Whole Foods Market, Inc. (NASDAQ: WFM) shares have lost 12 percent since December 28, while shares of Bristol-Myers Squibb Co (NYSE: BMY) are down 7 percent. BMO Capital Markets analysts downgraded the ratings and reduced the price targets of both companies. While Whole Foods’...
-
BMO Thinks Valeant's Structure Is 'Questionable,' Says Investigation May Be Needed To Resolve Uncertainty
Thursday, October 22, 2015 - 9:39am | 336Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares have slumped 48 percent in the last month, and are trading significantly below their 52-week high of $263.81. BMO Capital Markets’ Alex Arfaei downgraded the rating on the company to Market Perform, while reducing the price target to...
-
Calls Of Note: Wall Street Research Moving The Market On Thursday
Thursday, August 13, 2015 - 1:35pm | 1224Read More...The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." Morgan Stanley: Initiating Intercept Pharmaceutical At Underperform Andrew Berens of Morgan Stanley initiated coverage of Intercept Pharmaceuticals...
-
BMO Downgrades Zoetis After Valeant Report
Friday, June 26, 2015 - 12:36pm | 182Read More...In a report published Friday, BMO Capital analyst Alex Arfaei downgraded the rating on Zoetis Inc (NYSE: ZTS) from Outperform to Market Perform, while raising the price target from $51 to $57, following the almost 29 percent increase in the share price year-to-date. The analyst believes that the...
-
UPDATE: BMO Capital Downgrades Pfizer
Monday, July 28, 2014 - 9:36am | 76Read More...In a report released Monday, BMO Capital analyst Alex Arfaei downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform while reducing its price target from $34 to $31. Analysts at BMO stated Pfizer has "limited growth prospects." Pfizer's new drug releases do not outweigh...
-
UPDATE: BMO Downgrades Bristol-Myers Squibb
Thursday, May 15, 2014 - 10:37am | 135Read More...BMO downgraded Bristol-Myers Squibb (NYSE: BMY) from Outperform to a Market Perform rating. Alex Arfaei said, "We were wrong to extrapolate the strong efficacy seen with Bristol's Nivo+Yervoy combo in melanoma to lung (NSCLC) and kidney (RCC) cancer." Arfaei later went on to say, "Although BMS...
-
UPDATE: BMO Capital Upgrades Eli Lilly
Tuesday, April 8, 2014 - 12:18pm | 150Read More...On Tuesday, BMO Capital upgraded shares of Eli Lilly (NYSE: LLY) from Underperform to Market Perform and raised the price target from $50 to $62. “The upholding of the Alimta patent and the recent Bemaciclib data at AACR this week significantly altered the valuation of the company,” analyst Alex...
-
UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive Outlook
Monday, February 10, 2014 - 11:02am | 122Read More...In a report published Monday, BMO Capital Markets analyst Alex Arfaei upgraded the rating on Bristol-Myers Squibb (NYSE: BMY) from Market Perform to Outperform, and raised the price target from $56.00 to $60.00. In the report, BMO Capital Markets noted, “We are upgrading BMY to Outperform from...
-
Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment
Friday, January 24, 2014 - 4:21pm | 155Read More...Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3. BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a...
-
UPDATE: BMO Capital Markets Lowers PT on Merck Following New SGLT2 Data
Monday, June 24, 2013 - 9:30am | 173Read More...In a report published Monday, BMO Capital Markets analyst Alex Arfaei reiterated an Outperform rating on Merck (NYSE: MRK), but lowered the price target from $54.00 to $52.00. In the report, BMO Capital Markets noted, “New data from SGLT2 drugs presented at the ADA and supporting expert...
